CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 217 filers reported holding CLOVIS ONCOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $31,400,000 | -14.7% | 690,563 | -1.0% | 0.03% | -16.2% |
| Q1 2018 | $36,832,000 | -10.3% | 697,576 | +15.6% | 0.04% | -9.8% |
| Q4 2017 | $41,050,000 | -17.0% | 603,672 | +0.6% | 0.04% | -19.6% |
| Q3 2017 | $49,454,000 | -55.4% | 600,169 | -49.4% | 0.05% | -56.8% |
| Q2 2017 | $110,968,000 | +374.2% | 1,185,177 | +222.5% | 0.12% | +372.0% |
| Q1 2017 | $23,399,000 | +17.0% | 367,500 | -18.4% | 0.02% | +13.6% |
| Q4 2016 | $20,000,000 | +31.9% | 450,247 | +7.0% | 0.02% | +37.5% |
| Q3 2016 | $15,167,000 | +297.6% | 420,730 | +638.7% | 0.02% | +300.0% |
| Q2 2013 | $3,815,000 | – | 56,959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
| Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
| Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
| Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
| HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
| PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
| NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
| PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
| Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |